Novavax secures $384M for Covid-19 vaccine program
Novavax Inc. just got a significant investment to advance its Covid-19 vaccine candidate.
The Oslo, Norway-based Coalition for Epidemic Preparedness Innovations, a foundation that invests in vaccine development for emerging infectious diseases, plans to invest up to $384 million to push the candidate through phase 2 clinical trials, the Gaithersburg biotech said Monday. The capital, on top of an initial $4 million from CEPI in March, would help the company increase production for this program —…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news
More News: Biotechnology | Clinical Trials | COVID-19 | Epidemics | Epidemiology | Health Management | Infectious Diseases | Norway Health | Pharmaceuticals | Vaccines